Biorg

Biorg is a biotechnology company focused on the development of functional human micro-tissues for regenerative medicine and drug development. The company's proprietary platform, originating from research at Stanford University, enables the creation of complex, vascularized organoids that closely replicate human organ structure and function. Biorg's initial focus is on lung tissue, aiming to treat devastating respiratory conditions such as idiopathic pulmonary fibrosis and COPD through cell-based therapies. By providing high-fidelity human tissue models, Biorg also facilitates more accurate preclinical testing for the broader pharmaceutical industry. The company is currently in the preclinical stage and is backed by leading venture capital firms.